Adam C. Salisbury

ORCID: 0000-0003-1161-6356
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Coronary Interventions and Diagnostics
  • Cardiac Imaging and Diagnostics
  • Acute Myocardial Infarction Research
  • Peripheral Artery Disease Management
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Erythropoietin and Anemia Treatment
  • Cardiac, Anesthesia and Surgical Outcomes
  • Blood transfusion and management
  • Venous Thromboembolism Diagnosis and Management
  • Vascular Procedures and Complications
  • Cardiac Arrest and Resuscitation
  • Health Systems, Economic Evaluations, Quality of Life
  • Lipoproteins and Cardiovascular Health
  • Heart Failure Treatment and Management
  • Cardiac Health and Mental Health
  • Hemoglobinopathies and Related Disorders
  • Cerebrovascular and Carotid Artery Diseases
  • Cardiovascular Function and Risk Factors
  • Cardiac Valve Diseases and Treatments
  • Acute Kidney Injury Research
  • Pain Management and Treatment
  • Atrial Fibrillation Management and Outcomes
  • COVID-19 and Mental Health
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Iron Metabolism and Disorders

University of Missouri–Kansas City
2015-2024

Saint Luke's Hospital
2015-2024

University of Washington
2017-2023

Cardiovascular Research Foundation
2023

Saint Luke's Health System
2012-2022

Missouri Heart Center
2017-2019

Salisbury University
2011-2018

University of Chicago Medical Center
2018

Monash Health
2017

Monash University
2017

Background— Improving patients’ quality of life is a primary indication for percutaneous coronary intervention (PCI), yet little known about patient characteristics associated with greater quality-of-life improvement from the procedure. This study was conducted to identify benefit after PCI. Methods and Results— A consecutive series 1518 patients undergoing PCI in nonacute myocardial infarction settings were prospectively enrolled into an observational documenting their postprocedural health...

10.1161/01.cir.0000150392.70749.c7 article EN Circulation 2004-12-21

<h3>Background</h3>Hospital-acquired anemia (HAA) during acute myocardial infarction (AMI) is associated with higher mortality and worse health status often develops in the absence of recognized bleeding. The extent to which diagnostic phlebotomy, a modifiable process care, contributes HAA unknown.<h3>Methods</h3>We studied 17 676 patients AMI from 57 US hospitals included contemporary database January 1, 2000, through December 31, 2008, who were not anemic at admission but developed...

10.1001/archinternmed.2011.361 article EN Archives of Internal Medicine 2011-08-09

Same-day discharge (SDD) after elective percutaneous coronary intervention (PCI) is associated with lower costs and preferred by patients. However, to our knowledge, contemporary patterns of SDD PCI respect the incidence, hospital variation, trends, costs, safety outcomes in United States are unknown.To examine (1) incidence trends SDD; (2) variation (3) association between readmissions for bleeding, acute kidney injury (AKI), myocardial infarction (AMI), or mortality at 30, 90, 365 days...

10.1001/jamacardio.2018.3029 article EN JAMA Cardiology 2018-09-29

Background— Anemia is common among patients hospitalized with acute myocardial infarction and associated poor outcomes. Less known about the incidence, correlates, prognostic implications of acute, hospital-acquired anemia (HAA). Methods Results— We identified 2909 who had normal hemoglobin (Hgb) on admission in multicenter TRIUMPH registry defined HAA by criteria proposed Beutler Waalen. used hierarchical Poisson regression to identify independent correlates multivariable proportional...

10.1161/circoutcomes.110.957050 article EN Circulation Cardiovascular Quality and Outcomes 2010-05-21

Benefits of drug-eluting stents (DES) in percutaneous coronary intervention (PCI) are greatest those at the highest risk target-vessel revascularization (TVR). Drug-eluting cost more than bare-metal (BMS) and necessitate prolonged dual antiplatelet therapy (DAPT), which increases costs, bleeding risk, complications if DAPT is prematurely discontinued. Our objective was to assess whether DES preferentially used patients with higher predicted TVR estimate lower use low-TVR-risk would be...

10.1001/archinternmed.2012.3093 article EN Archives of Internal Medicine 2012-07-09

We sought to determine the impact of subintimal plaque modification (SPM) on early health status following unsuccessful chronic total occlusion (CTO) PCI.Intentionally dilating space during CTO PCI facilitate flow through dissection planes and improve success repeat attempts is a technique used by some hybrid operators, may restoring distal vessel despite PCI.We studied 138 patients who underwent in 12-center registry. Safety was assessed comparing in-hospital outcomes undergoing with...

10.1002/ccd.27380 article EN Catheterization and Cardiovascular Interventions 2017-10-25

The aim of this study was to evaluate the cost-effectiveness drug-coated balloon (DCB) angioplasty versus standard percutaneous transluminal (PTA).Recent trials have reported lower rates target lesion revascularization with DCB PTA. However, is unknown.A prospective economic performed alongside IN.PACT SFA II (IN.PACT Admiral Drug-Coated Balloon vs. Standard Angioplasty for Treatment Superficial Femoral Artery [SFA] and Proximal Popliteal [PPA]) trial, which randomized 181 patients...

10.1016/j.jcin.2016.08.036 article EN cc-by-nc-nd КАРДИОЛОГИЯ УЗБЕКИСТАНА 2016-11-01

Objectives To determine whether a variation of an abandoned antegrade percutaneous coronary intervention (PCI) technique, termed subintimal tracking and reentry (STAR), could be safe effective strategy to contend with complex chronic total occlusions (CTO) when other strategies fail. Background Complex CTOs require advanced techniques such as the retrograde approach, which is associated higher complication rates than strategies. Methods The medical records 32 consecutive patients who...

10.1002/ccd.27783 article EN Catheterization and Cardiovascular Interventions 2018-11-09
Jeffrey L. Carson Maria M. Brooks Bernard R. Chaitman John H. Alexander Shaun G. Goodman and 95 more Marnie Bertolet J. Dawn Abbott Howard A. Cooper Sunil V. Rao Darrell J. Triulzi Dean Fergusson William J. Kostis Helaine Noveck Tabassome Simon Philippe Gabríel Steg Andrew P. DeFilippis Andrew M. Goldsweig Renato D. Lópes Harvey D. White Caroline Alsweiler Erin Morton Paul C. Hébert Jeffrey L. Carson Shahab Ghafghazi Howard A. Cooper Frances O. Wood Mark Menegus Barry F. Uretsky Srikanth Vallurupalli Gregory Maniatis Luis Gruberg Robert O. Roswell Joseph S. Rossi Farhad Abtahian Meechai Tessalee Gregory W. Barsness J. Dawn Abbott Herbert D. Aronow Kodangudi B. Ramanathan Mark Schmidhofer Friederike K. Keating Michael Carson Michael C. Kontos Mansoor Qureshi Stacey Clegg Warren K. Laskey Tamar S. Polonsky Rajesh Gupta Mujeeb Sheikh Lynne Uhl Paul Mullen Arthur Bracey William Matthai Christopher P. Stowell David M. Dudzinski Gregary Marhefka Perry Weinstock William Lawson Norma Keller Eugene Yuriditsky Michael A. Thomas Alice Jacobs Claudia P. Hochberg Omar K. Siddiqi Joshua Schulman‐Marcus Mikhail Torosoff Michael Gitter Xuming Dai Jay H. Traverse Eric McCamant Jason Scott Rajesh V. Swaminathan Sunil V. Rao Andrew M. Goldsweig Andrew P. DeFilippis Adam C. Salisbury David Landers Ganesh Raveendran Ramin Ebrahimi Richard G. Bach Joseph M. Delehanty Raj C. Shah Sorin J. Brener Jonathan Doroshow Adriano Caixeta Dalton Bertolim Précoma Frederico Toledo Campo Dall’Orto Pedro Beraldo de Andrade Marianna Deway Andrade Dracoulakis Lília Nigro Maia Luiz Eduardo Fontelles Ritt Alexandre Schaan de Quadros Dário Celestino Sobral Filho Fernando De Martino Thao Huynh Greg Schnell Manohara Senaratne Vikas Tandon Vikas Tandon John Neary

10.1016/j.ahj.2022.11.015 article EN publisher-specific-oa American Heart Journal 2022-11-20
Gerard Portela Jeffrey L. Carson Sonja A. Swanson John H. Alexander Paul C. Hébert and 95 more Shaun G. Goodman Philippe Gabríel Steg Marnie Bertolet Jordan B. Strom Dean Fergusson Tabassome Simon Harvey D. White Howard A. Cooper J. Dawn Abbott Sunil V. Rao Bernard R. Chaitman Christopher B. Fordyce Renato D. Lópes Benoit Daneault Maria M. Brooks Adam C. Salisbury Adam Gershon Adedayo Adeboye Adriana Carbonaro Adriano Caixeta A. Garvey Rene Agnes Y.Y. Lee Ahmad Mizyed Ahmed Hassanin A. Kone A. Cherian Akshay Bagai Alana Gulliver Aleisha Easton Alexandra Rousseau Alexandre Gautier Alexandre Schaan de Quadros Alexia Dantigny Alexia Ep Ali Ghamraoui Alice Jacobs Aline Giacomo Allison Schley Amanda Barnett Amanda Bollino Amanda Logan Amanda Salvatore Amanda Tice Amandine Grelier Amandine Ruissel Ameen Patel Ami Patel Amina Zamiti-Smondel Amy McMeans Andrea Sarafolean Andrew Baker Andrew M. Goldsweig Andrew P. DeFilippis Andrew Starovoytov Angeline Camilo Angélique Andrieu Angie Adler Anh-Phuong Pham Anna Helena Felipe Pereira Centurione Anna Koulova Anna S. Law Anna Tran Anne Druart Antoine Fayol Antoine Léquipar Anuritha Tirumani Anushka Jayasekara Araceli Boan Arav Jhand Ariel Diaz Arlete Matos Arnaud Ferrante Arthur Bracey Arthur Darmon Arthur Ramonatxo A. Aravind Asha Mellor Ashley Armstrong A. Adam Ata ur Rehman Quraishi Attílio Galhardo Audrey Cailliau Aurélie Gutehrle Axelle Fuentes Barbara Gallagher Barbara A. Konkle Barbara Shannon Barbara Shimada-Krouwer Barinder Hansra Barry H. Kaplan Barry F. Uretsky Basile Verdier Batric Popovic Baya Mahtout Behram Mody

The optimal hemoglobin threshold to guide red blood cell (RBC) transfusion for patients with acute myocardial infarction (MI) and anemia is uncertain. To estimate the efficacy of 4 individual thresholds (<10 g/dL [<100 g/L], <9 [<90 <8 [<80 <7 [<70 g/L]) in MI anemia. Prespecified secondary analysis MINT (Myocardial Ischemia Transfusion) trial using target emulation methods. (ClinicalTrials.gov: NCT02981407). 144 clinical sites 6 countries. 3492 participants a level below 10 g/dL. Four...

10.7326/m24-0571 article EN Annals of Internal Medicine 2024-09-30

Health status and quality of life improvement after chronic total occlusion (CTO) percutaneous coronary intervention (PCI) among patients with refractory angina has not been reported. We sought to determine the degree CTO PCI in angina.Among 1000 consecutive who underwent a 12-center registry, was defined as any (baseline Seattle Angina Questionnaire [SAQ] Frequency score ≤90) despite treatment ≥3 antianginal medications. at baseline 1-year follow-up quantified using SAQ. Refractory present...

10.1161/circinterventions.118.007558 article EN Circulation Cardiovascular Interventions 2019-03-01

Intracoronary (IC) imaging for percutaneous coronary intervention (PCI) is associated with better patient outcomes and carries a class IIA guideline recommendation, but it remains rarely used. We sought to characterize hospital-level variability in IC PCI the United States identify factors that may explain this variability.

10.1016/j.jscai.2023.100973 article EN cc-by-nc-nd Journal of the Society for Cardiovascular Angiography & Interventions 2023-05-19
Coming Soon ...